A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3816-3822

  Smith, Ian E ^a   Walsh, Geraldine ^a   Skene, Anthony ^a   Llombart, Antonio ^a   Mayordomo, José Ignacio ^a   Detre, Simone ^a   Salter, Janine ^a   Clark, Emma ^a   Magill, Patrick ^a   Dowsett, Mitch ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; GEFITINIB; KI 67 ANTIGEN; PLACEBO; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTRADIOL; HER1 PROTEIN, HUMAN; NITRILE; PROGESTERONE RECEPTOR; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DRY SKIN; EARLY CANCER; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HYPERTROCHOSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; BREAST TUMOR; MASTECTOMY; METABOLISM; PHASE 2 CLINICAL TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; KI-67 ANTIGEN; MASTECTOMY; NITRILES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 34548537574     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.6578     Document Type: Article

References (27)

1. Johnston SR, Head J, Pancholi S, et al: Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9:524S-532S, 2003
2. Chan CM, Martin LA, Johnston SR, et al: Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81:333-341, 2002
3. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754, 2002
4. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
5. Martin LA, Farmer I, Johnston SR, et al: Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 287:30458-30468, 2003
6. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changed during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer- a study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005
7. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002
8. Horne GM, Angus B, Wright C, et al: Relationships between oestrogen receptor, epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer J Pathol 155:143-150, 1988
9. Tsutsui S, Ohno S, Murakami S, et al: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor Status in 1029 patients with breast cancer. Breast Cancer Res Treat 71:67-75, 2002
10. Newby JC, A'Hern RP, Leek RD, et al: Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: Validation against ligand-binding assay and clinical relevance in breast cancer. Br J Cancer 71:1237-1242, 1995
11. The World Medical Association: The Declaration of Helsinki. http://www.wma.net/e/policy/b3htm
12. Ellis PA, Smith IE, Detre S, et al: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48:107-116, 1998
13. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
14. Dowsett M, Goss PE, Powles TJ, et al: Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimisation of therapeutic dose and route. Cancer Res 47:1957-1961, 1987
15. Jones HK, Stafford LE, Swaisland HC, et al: A sensitive assay for ZD1839 ('Iressa') in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: Validation and use in phase I clinical trials. J Pharm Biomed Anal 29:221-228, 2002
16. Chan KC, Knox WF, Gee JM, et al: Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 62:122-128, 2002
17. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23:5108-5116, 2005
18. Finn RS, Dering C, Ginther M, et al: ER+ PR-breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. J Clin Oncol 24:6s, 2006 (abstr 514)
19. Arpino G, Weiss H, Lee AV, et al: Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261, 2005
20. Baselga J, Albanell J, Amparo R, et al: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5333, 2005
21. von Minckwitz G, Jonat W, Fasching P, et al: A multicentre phase II study on gefitinib in taxane-and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89:165-172, 2005
22. Polychronis A, Sinnett HD, Hadjiminis D, et al: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncology 6:383-391, 2005
23. Agrawal A, Gutteridge E, Cheung KL, et al: Efficacy and tolerability of gefitinib in oestrogen receptor negative and tamoxifen resistant oestrogen receptor positive locally advanced or metastatic breast cancer. Proc San Antonio Breast Cancer Symp, 2005 (abstr 1065)
24. Ciardiello F, Troiani T, Caputo F, et al: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94:1604-1609, 2006
25. Gasparini G, Sarmiento R, Amici S, et al: Gefitnib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: A phase I study with biological correlate. Ann Oncol 16:1867-1873, 2005
26. Fountzilas G, Pectasides D, Kalogera-Fountzila A, et al: Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 92:1-9, 2005
27. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001